<div id="readability-page-1"><p>Thompson Davis &amp; CO. Inc. acquired a new stake in  CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  acquired 16,529 shares of the pharmacy operator's stock, valued at approximately $1,140,000.</p><ul><li>CVS Health Gains as Revenue Grows, Dividend Remains Strong</li></ul><p>Several other hedge funds and other institutional investors have also modified their holdings of CVS. FineMark National Bank &amp; Trust raised its holdings in  CVS Health by 1.7% in the 2nd quarter. FineMark National Bank &amp; Trust now owns 9,576 shares of the pharmacy operator's stock valued at $661,000 after acquiring an additional 157 shares during the period.  Smartleaf Asset Management LLC grew its position in shares of  CVS Health by 1.1% in the second quarter. Smartleaf Asset Management LLC now owns 15,059 shares of the pharmacy operator's stock valued at $1,031,000 after purchasing an additional 164 shares during the last quarter.  Hazlett Burt &amp; Watson Inc. increased its stake in shares of  CVS Health by 10.9% during the second quarter. Hazlett Burt &amp; Watson Inc. now owns 1,682 shares of the pharmacy operator's stock worth $117,000 after purchasing an additional 165 shares during the period.  Loomis Sayles &amp; Co. L P lifted its holdings in  CVS Health by 11.0% during the 2nd quarter. Loomis Sayles &amp; Co. L P now owns 1,674 shares of the pharmacy operator's stock worth $115,000 after purchasing an additional 166 shares during the last quarter.  Finally, Williams Financial LLC boosted its stake in  CVS Health by 2.5% in the 2nd quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator's stock valued at $478,000 after purchasing an additional 167 shares during the period. Institutional investors own  80.66% of the company's stock. </p><h2>CVS Health Stock Performance</h2><p>Shares of CVS Health stock opened at $79.45 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.63 and a debt-to-equity ratio of 0.83. The company has a market cap of $100.85 billion, a PE ratio of 209.08, a price-to-earnings-growth ratio of 0.78 and a beta of 0.48. The company has a 50 day moving average of $78.97 and a 200-day moving average of $71.91. CVS Health Corporation has a 1-year low of $43.56 and a 1-year high of $85.15. </p><ul><li>MarketBeat Week in Review – 05/12 - 05/16</li></ul><p>CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The business had revenue of $102.87 billion for the quarter, compared to analysts' expectations of $98.85 billion. During the same period last year, the firm posted $1.09 earnings per share. The firm's quarterly revenue was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS.  As a group, equities research analysts forecast that  CVS Health Corporation will post 5.89 earnings per share for the current fiscal year. </p><h2>CVS Health Dividend Announcement</h2><p>The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Investors of record on Thursday, October 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.3%. CVS Health's dividend payout ratio (DPR) is 700.00%. </p><h2>Wall Street Analyst Weigh In</h2><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>A number of equities research analysts have recently weighed in on the company. Sanford C. Bernstein lifted their target price on CVS Health from $86.00 to $87.00 and gave the stock a &#34;market perform&#34; rating in a report on Friday. UBS Group  reiterated an &#34;outperform&#34; rating on shares of CVS Health in a research note on Wednesday. Mizuho boosted their price objective on shares of CVS Health from $88.00 to $95.00 and gave the company an &#34;outperform&#34; rating in a report on Wednesday. Morgan Stanley raised their target price on shares of CVS Health from $89.00 to $93.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday. Finally, Leerink Partners boosted their price target on CVS Health from $86.00 to $95.00 and gave the company an &#34;outperform&#34; rating in a research note on Thursday, October 16th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned  a Buy rating and four have issued  a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $93.71.</p><p><b>Check Out Our Latest Research Report on CVS</b></p><h2>CVS Health Company Profile</h2> (Free Report)<p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p><h2>See Also</h2><ul><li>Five stocks we like better than CVS Health</li><li>Why is the Ex-Dividend Date Significant to Investors?</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li><li>The How And Why of Investing in Oil Stocks</li><li>Why Amazon Could Be a $300 Stock Within Weeks</li><li>What Are Dividends? Buy the Best Dividend Stocks</li><li>Adobe Gets Post-Earnings Lift: Long-Term Outlook Favors Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CVS Health Right Now?</h2><p>Before you consider CVS Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Thompson Davis & CO. Inc. invested $1.14 million in CVS Health Corporation during Q2, acquiring 16,529 shares. Other institutional investors also adjusted their holdings. CVS Health reported strong quarterly earnings, beating estimates with $1.60 EPS and $102.87 billion revenue. Analysts have raised target prices, with ratings ranging from "market perform" to "outperform." CVS Health's dividend yield is 3.3%, with a payout ratio of 700%. Institutional investors own 80.66% of CVS stock.</p>

Thompson Davis & CO. Inc. Makes New $1.14 Million Investment in CVS Health Corporation $CVS